PL3122878T3 - TERAPIA mRNA DO LECZENIA CHORÓB OCZU - Google Patents
TERAPIA mRNA DO LECZENIA CHORÓB OCZUInfo
- Publication number
- PL3122878T3 PL3122878T3 PL15767977T PL15767977T PL3122878T3 PL 3122878 T3 PL3122878 T3 PL 3122878T3 PL 15767977 T PL15767977 T PL 15767977T PL 15767977 T PL15767977 T PL 15767977T PL 3122878 T3 PL3122878 T3 PL 3122878T3
- Authority
- PL
- Poland
- Prior art keywords
- treatment
- ocular diseases
- mrna therapy
- mrna
- therapy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461969483P | 2014-03-24 | 2014-03-24 | |
PCT/US2015/021403 WO2015148247A1 (en) | 2014-03-24 | 2015-03-19 | Mrna therapy for the treatment of ocular diseases |
EP15767977.0A EP3122878B1 (en) | 2014-03-24 | 2015-03-19 | Mrna therapy for the treatment of ocular diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
PL3122878T3 true PL3122878T3 (pl) | 2019-06-28 |
Family
ID=54196241
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL15767977T PL3122878T3 (pl) | 2014-03-24 | 2015-03-19 | TERAPIA mRNA DO LECZENIA CHORÓB OCZU |
Country Status (15)
Country | Link |
---|---|
US (2) | US20170143848A1 (pl) |
EP (3) | EP3699274A1 (pl) |
CY (1) | CY1121348T1 (pl) |
DK (2) | DK3450553T3 (pl) |
ES (2) | ES2774552T3 (pl) |
HR (1) | HRP20190117T1 (pl) |
HU (1) | HUE041940T2 (pl) |
LT (1) | LT3122878T (pl) |
ME (1) | ME03314B (pl) |
PL (1) | PL3122878T3 (pl) |
PT (1) | PT3122878T (pl) |
RS (1) | RS58337B1 (pl) |
SI (1) | SI3122878T1 (pl) |
TR (1) | TR201900649T4 (pl) |
WO (1) | WO2015148247A1 (pl) |
Families Citing this family (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT2506857T (pt) | 2009-12-01 | 2018-05-14 | Translate Bio Inc | Entrega de arnm para o acréscimo de proteínas e enzimas em doenças genéticas humanas |
CA2838063C (en) | 2011-06-08 | 2023-07-11 | Shire Human Genetic Therapies, Inc. | Cleavable lipids |
US9163284B2 (en) | 2013-08-09 | 2015-10-20 | President And Fellows Of Harvard College | Methods for identifying a target site of a Cas9 nuclease |
WO2015048744A2 (en) | 2013-09-30 | 2015-04-02 | Moderna Therapeutics, Inc. | Polynucleotides encoding immune modulating polypeptides |
CA2926218A1 (en) | 2013-10-03 | 2015-04-09 | Moderna Therapeutics, Inc. | Polynucleotides encoding low density lipoprotein receptor |
US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
US10077453B2 (en) | 2014-07-30 | 2018-09-18 | President And Fellows Of Harvard College | CAS9 proteins including ligand-dependent inteins |
EP3364981A4 (en) | 2015-10-22 | 2019-08-07 | ModernaTX, Inc. | VACCINE AGAINST THE HUMAN CYTOMEGALOVIRUS |
EP3365357B1 (en) | 2015-10-23 | 2024-02-14 | President and Fellows of Harvard College | Evolved cas9 proteins for gene editing |
EP3964200A1 (en) | 2015-12-10 | 2022-03-09 | ModernaTX, Inc. | Compositions and methods for delivery of therapeutic agents |
KR20180104635A (ko) | 2015-12-30 | 2018-09-21 | 코디악 사이언시스 인코포레이티드 | 항체 및 이의 접합체 |
US20210206818A1 (en) | 2016-01-22 | 2021-07-08 | Modernatx, Inc. | Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof |
WO2017180917A2 (en) | 2016-04-13 | 2017-10-19 | Modernatx, Inc. | Lipid compositions and their uses for intratumoral polynucleotide delivery |
AU2017306676B2 (en) | 2016-08-03 | 2024-02-22 | President And Fellows Of Harvard College | Adenosine nucleobase editors and uses thereof |
AU2017308889B2 (en) | 2016-08-09 | 2023-11-09 | President And Fellows Of Harvard College | Programmable Cas9-recombinase fusion proteins and uses thereof |
US11542509B2 (en) | 2016-08-24 | 2023-01-03 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
SG11201903089RA (en) | 2016-10-14 | 2019-05-30 | Harvard College | Aav delivery of nucleobase editors |
JP6980780B2 (ja) | 2016-10-21 | 2021-12-15 | モデルナティーエックス, インコーポレイテッド | ヒトサイトメガロウイルスワクチン |
US20190275071A1 (en) * | 2016-11-23 | 2019-09-12 | Mayo Foundation For Medical Education And Research | Particle-mediated delivery of biologics |
WO2018119359A1 (en) | 2016-12-23 | 2018-06-28 | President And Fellows Of Harvard College | Editing of ccr5 receptor gene to protect against hiv infection |
EP3971291A1 (en) | 2017-02-27 | 2022-03-23 | Translate Bio, Inc. | Methods for purification of messenger rna |
AU2018224318A1 (en) | 2017-02-27 | 2019-09-19 | Translate Bio, Inc. | Methods for purification of messenger RNA |
WO2018165504A1 (en) | 2017-03-09 | 2018-09-13 | President And Fellows Of Harvard College | Suppression of pain by gene editing |
US11542496B2 (en) | 2017-03-10 | 2023-01-03 | President And Fellows Of Harvard College | Cytosine to guanine base editor |
IL306092A (en) | 2017-03-23 | 2023-11-01 | Harvard College | Nucleic base editors that include nucleic acid programmable DNA binding proteins |
WO2018209320A1 (en) | 2017-05-12 | 2018-11-15 | President And Fellows Of Harvard College | Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation |
WO2018213731A1 (en) | 2017-05-18 | 2018-11-22 | Modernatx, Inc. | Polynucleotides encoding tethered interleukin-12 (il12) polypeptides and uses thereof |
JP2020534795A (ja) | 2017-07-28 | 2020-12-03 | プレジデント アンド フェローズ オブ ハーバード カレッジ | ファージによって支援される連続的進化(pace)を用いて塩基編集因子を進化させるための方法および組成物 |
US20190300856A1 (en) * | 2017-08-16 | 2019-10-03 | Georgia Tech Research Corporation | Messenger RNA based expression of opsins and reporter proteins for electrophysiologic characterization of in vitro neurons and cardiomyocytes |
WO2019139645A2 (en) | 2017-08-30 | 2019-07-18 | President And Fellows Of Harvard College | High efficiency base editors comprising gam |
US11795443B2 (en) | 2017-10-16 | 2023-10-24 | The Broad Institute, Inc. | Uses of adenosine base editors |
WO2019169228A1 (en) * | 2018-03-01 | 2019-09-06 | Georgia Tech Research Corporation | Methods and compositions for mrna-based modulation and detection of cell phenotypes |
CA3103436A1 (en) | 2018-06-11 | 2019-12-19 | The Regents Of The University Of California | Demethylation to treat eye disease |
CA3108544A1 (en) | 2018-08-24 | 2020-02-27 | Translate Bio, Inc. | Methods for purification of messenger rna |
AU2019335055A1 (en) | 2018-09-04 | 2021-03-25 | The Board Of Regents Of The University Of Texas System | Compositions and methods for organ specific delivery of nucleic acids |
JP7425066B2 (ja) | 2018-09-04 | 2024-01-30 | ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム | 核酸を臓器特異的送達するための組成物および方法 |
EP3864163B1 (en) | 2018-10-09 | 2024-03-20 | The University of British Columbia | Compositions and systems comprising transfection-competent vesicles free of organic-solvents and detergents and methods related thereto |
CA3115119A1 (en) | 2018-11-08 | 2020-05-14 | Translate Bio, Inc. | Methods and compositions for messenger rna purification |
WO2020097511A2 (en) * | 2018-11-09 | 2020-05-14 | Translate Bio, Inc. | Messenger rna therapy for treatment of ocular diseases |
US11559561B2 (en) | 2019-01-07 | 2023-01-24 | Translate Bio, Inc. | Composition and methods for treatment of primary ciliary dyskinesia |
EP3920950A1 (en) * | 2019-02-08 | 2021-12-15 | CureVac AG | Coding rna administered into the suprachoroidal space in the treatment of ophtalmic diseases |
JP2022526908A (ja) | 2019-03-19 | 2022-05-27 | ザ ブロード インスティテュート,インコーポレーテッド | 編集ヌクレオチド配列を編集するための方法および組成物 |
CN114786731A (zh) | 2019-10-10 | 2022-07-22 | 科达制药股份有限公司 | 治疗眼部病症的方法 |
AU2021267940A1 (en) | 2020-05-08 | 2022-12-08 | President And Fellows Of Harvard College | Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence |
US11406703B2 (en) | 2020-08-25 | 2022-08-09 | Modernatx, Inc. | Human cytomegalovirus vaccine |
TW202233232A (zh) | 2020-11-06 | 2022-09-01 | 法商賽諾菲公司 | 遞送mRNA疫苗的脂質奈米顆粒 |
US11524023B2 (en) | 2021-02-19 | 2022-12-13 | Modernatx, Inc. | Lipid nanoparticle compositions and methods of formulating the same |
JP2024515035A (ja) * | 2021-04-01 | 2024-04-04 | モデルナティエックス インコーポレイテッド | mRNAによる抗体構造及びアイソタイプの粘膜発現 |
CA3230031A1 (en) | 2021-09-03 | 2023-03-09 | Patrick Baumhof | Novel lipid nanoparticles for delivery of nucleic acids |
WO2023073228A1 (en) | 2021-10-29 | 2023-05-04 | CureVac SE | Improved circular rna for expressing therapeutic proteins |
WO2023077148A1 (en) | 2021-11-01 | 2023-05-04 | Tome Biosciences, Inc. | Single construct platform for simultaneous delivery of gene editing machinery and nucleic acid cargo |
WO2023122764A1 (en) | 2021-12-22 | 2023-06-29 | Tome Biosciences, Inc. | Co-delivery of a gene editor construct and a donor template |
WO2023144330A1 (en) | 2022-01-28 | 2023-08-03 | CureVac SE | Nucleic acid encoded transcription factor inhibitors |
WO2023205744A1 (en) | 2022-04-20 | 2023-10-26 | Tome Biosciences, Inc. | Programmable gene insertion compositions |
WO2023215831A1 (en) | 2022-05-04 | 2023-11-09 | Tome Biosciences, Inc. | Guide rna compositions for programmable gene insertion |
WO2023225670A2 (en) | 2022-05-20 | 2023-11-23 | Tome Biosciences, Inc. | Ex vivo programmable gene insertion |
WO2023227608A1 (en) | 2022-05-25 | 2023-11-30 | Glaxosmithkline Biologicals Sa | Nucleic acid based vaccine encoding an escherichia coli fimh antigenic polypeptide |
WO2024020587A2 (en) | 2022-07-22 | 2024-01-25 | Tome Biosciences, Inc. | Pleiopluripotent stem cell programmable gene insertion |
WO2024089638A1 (en) | 2022-10-28 | 2024-05-02 | Glaxosmithkline Biologicals Sa | Nucleic acid based vaccine |
Family Cites Families (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
US4500707A (en) | 1980-02-29 | 1985-02-19 | University Patents, Inc. | Nucleosides useful in the preparation of polynucleotides |
US5132418A (en) | 1980-02-29 | 1992-07-21 | University Patents, Inc. | Process for preparing polynucleotides |
US4668777A (en) | 1981-03-27 | 1987-05-26 | University Patents, Inc. | Phosphoramidite nucleoside compounds |
US4973679A (en) | 1981-03-27 | 1990-11-27 | University Patents, Inc. | Process for oligonucleo tide synthesis using phosphormidite intermediates |
US4415732A (en) | 1981-03-27 | 1983-11-15 | University Patents, Inc. | Phosphoramidite compounds and processes |
US4373071A (en) | 1981-04-30 | 1983-02-08 | City Of Hope Research Institute | Solid-phase synthesis of polynucleotides |
US4401796A (en) | 1981-04-30 | 1983-08-30 | City Of Hope Research Institute | Solid-phase synthesis of polynucleotides |
US4897355A (en) | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US4737323A (en) | 1986-02-13 | 1988-04-12 | Liposome Technology, Inc. | Liposome extrusion method |
US5153319A (en) | 1986-03-31 | 1992-10-06 | University Patents, Inc. | Process for preparing polynucleotides |
US5047524A (en) | 1988-12-21 | 1991-09-10 | Applied Biosystems, Inc. | Automated system for polynucleotide synthesis and purification |
US5262530A (en) | 1988-12-21 | 1993-11-16 | Applied Biosystems, Inc. | Automated system for polynucleotide synthesis and purification |
FR2645866B1 (fr) | 1989-04-17 | 1991-07-05 | Centre Nat Rech Scient | Nouvelles lipopolyamines, leur preparation et leur emploi |
US5334761A (en) | 1992-08-28 | 1994-08-02 | Life Technologies, Inc. | Cationic lipids |
US5885613A (en) | 1994-09-30 | 1999-03-23 | The University Of British Columbia | Bilayer stabilizing components and their use in forming programmable fusogenic liposomes |
US5700642A (en) | 1995-05-22 | 1997-12-23 | Sri International | Oligonucleotide sizing using immobilized cleavable primers |
US5744335A (en) | 1995-09-19 | 1998-04-28 | Mirus Corporation | Process of transfecting a cell with a polynucleotide mixed with an amphipathic compound and a DNA-binding protein |
EP2292771A3 (en) * | 1997-09-19 | 2011-07-27 | Life Technologies Corporation | Sense mRNA therapy |
WO2005007810A2 (en) * | 2003-06-16 | 2005-01-27 | Grinstaff Mark W | Functional synthetic molecules and macromolecules for gene delivery |
US7799565B2 (en) | 2004-06-07 | 2010-09-21 | Protiva Biotherapeutics, Inc. | Lipid encapsulated interfering RNA |
BRPI0610499A2 (pt) * | 2005-04-12 | 2010-06-22 | Intradigm Corp | moléculas de ácido nucléico , composições e usos das referidas moléculas |
JP5000638B2 (ja) | 2005-04-18 | 2012-08-15 | アンスティテュー・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル・(イ・エヌ・エス・ウ・エール・エム) | 対象の眼球に対して治療用生成物を送達するための改良型方法及び装置 |
CA2659301A1 (en) | 2006-07-28 | 2008-02-07 | Applera Corporation | Dinucleotide mrna cap analogs |
DE102007001370A1 (de) | 2007-01-09 | 2008-07-10 | Curevac Gmbh | RNA-kodierte Antikörper |
WO2008137066A1 (en) | 2007-05-02 | 2008-11-13 | The Board Of Regents Of The University Of Oklahoma | Use of compacted nucleic acid nanoparticles in non-viral treatments of ocular diseases |
WO2009058911A2 (en) | 2007-10-31 | 2009-05-07 | Applied Biosystems Inc. | Preparation and isolation of 5' capped mrna |
US9139554B2 (en) | 2008-10-09 | 2015-09-22 | Tekmira Pharmaceuticals Corporation | Amino lipids and methods for the delivery of nucleic acids |
MX2011004859A (es) | 2008-11-07 | 2011-08-03 | Massachusetts Inst Technology | Lipidoides de aminoalcohol y usos de los mismos. |
PT2506857T (pt) | 2009-12-01 | 2018-05-14 | Translate Bio Inc | Entrega de arnm para o acréscimo de proteínas e enzimas em doenças genéticas humanas |
EP2538929A4 (en) | 2010-02-25 | 2014-07-09 | Univ Johns Hopkins | PROLONGED DELIVERY OF THERAPEUTIC AGENTS TO AN OCULAR COMPARTMENT |
US9019345B2 (en) | 2010-07-02 | 2015-04-28 | Intuitive Surgical Operations, Inc. | Imaging mode blooming suppression |
WO2012075040A2 (en) * | 2010-11-30 | 2012-06-07 | Shire Human Genetic Therapies, Inc. | mRNA FOR USE IN TREATMENT OF HUMAN GENETIC DISEASES |
ES2385080B1 (es) | 2010-12-21 | 2013-05-10 | Universidad Del Pais Vasco-Euskal Herriko Unibertsitatea | Nanopartículas lipídicas para el tratamiento de enfermedades oculares. |
TR201910686T4 (tr) * | 2011-06-08 | 2019-08-21 | Translate Bio Inc | Mrna iletimine yönelik lipit nanopartikül bileşimleri ve yöntemler. |
CA2838063C (en) | 2011-06-08 | 2023-07-11 | Shire Human Genetic Therapies, Inc. | Cleavable lipids |
EP4074694A1 (en) * | 2011-10-27 | 2022-10-19 | Massachusetts Institute Of Technology | Amino acid-, peptide- an polypeptide-lipids, isomers, compositions, an uses thereof |
EP2791160B1 (en) * | 2011-12-16 | 2022-03-02 | ModernaTX, Inc. | Modified mrna compositions |
EP2607375A1 (en) | 2011-12-21 | 2013-06-26 | The Provost, Fellows, Foundation Scholars, & the other members of Board, of the College of the Holy & Undiv. Trinity of Queen Elizabeth near Dublin | Variants of yeast NDI1 gene, and uses thereof in the treatment of disease associated with mitochondrial dysfunction. |
DK2830595T3 (da) * | 2012-03-29 | 2019-12-02 | Translate Bio Inc | Ioniserbare kationiske lipider |
US9877919B2 (en) * | 2012-03-29 | 2018-01-30 | Translate Bio, Inc. | Lipid-derived neutral nanoparticles |
AU2013243948A1 (en) | 2012-04-02 | 2014-10-30 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins associated with human disease |
TWI775096B (zh) * | 2012-05-15 | 2022-08-21 | 澳大利亞商艾佛蘭屈澳洲私營有限公司 | 使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd) |
LT2970456T (lt) * | 2013-03-14 | 2021-08-10 | Translate Bio, Inc. | Būdai ir kompozicijos, skirti mrnr koduojamų antikūnų pristatymui |
NZ718817A (en) * | 2013-10-22 | 2020-07-31 | Massachusetts Inst Technology | Lipid formulations for delivery of messenger rna |
EP3060258A1 (en) * | 2013-10-22 | 2016-08-31 | Shire Human Genetic Therapies, Inc. | Mrna therapy for phenylketonuria |
-
2015
- 2015-03-19 ES ES18201321T patent/ES2774552T3/es active Active
- 2015-03-19 SI SI201530559T patent/SI3122878T1/sl unknown
- 2015-03-19 DK DK18201321.9T patent/DK3450553T3/da active
- 2015-03-19 RS RS20190099A patent/RS58337B1/sr unknown
- 2015-03-19 EP EP19218561.9A patent/EP3699274A1/en active Pending
- 2015-03-19 EP EP18201321.9A patent/EP3450553B1/en active Active
- 2015-03-19 ME MEP-2019-13A patent/ME03314B/me unknown
- 2015-03-19 LT LTEP15767977.0T patent/LT3122878T/lt unknown
- 2015-03-19 DK DK15767977.0T patent/DK3122878T3/en active
- 2015-03-19 PT PT15767977T patent/PT3122878T/pt unknown
- 2015-03-19 EP EP15767977.0A patent/EP3122878B1/en active Active
- 2015-03-19 WO PCT/US2015/021403 patent/WO2015148247A1/en active Application Filing
- 2015-03-19 TR TR2019/00649T patent/TR201900649T4/tr unknown
- 2015-03-19 HU HUE15767977A patent/HUE041940T2/hu unknown
- 2015-03-19 PL PL15767977T patent/PL3122878T3/pl unknown
- 2015-03-19 ES ES15767977T patent/ES2707969T3/es active Active
- 2015-03-19 US US15/128,303 patent/US20170143848A1/en not_active Abandoned
-
2019
- 2019-01-18 HR HRP20190117TT patent/HRP20190117T1/hr unknown
- 2019-01-22 CY CY20191100085T patent/CY1121348T1/el unknown
-
2022
- 2022-02-03 US US17/592,335 patent/US20220354968A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
HRP20190117T1 (hr) | 2019-04-19 |
EP3699274A1 (en) | 2020-08-26 |
EP3450553B1 (en) | 2019-12-25 |
EP3122878A1 (en) | 2017-02-01 |
ES2707969T3 (es) | 2019-04-08 |
EP3450553A1 (en) | 2019-03-06 |
EP3122878B1 (en) | 2018-10-24 |
DK3122878T3 (en) | 2019-02-04 |
EP3122878A4 (en) | 2017-08-30 |
ES2774552T3 (es) | 2020-07-21 |
PT3122878T (pt) | 2019-02-01 |
US20170143848A1 (en) | 2017-05-25 |
ME03314B (me) | 2019-10-20 |
WO2015148247A1 (en) | 2015-10-01 |
DK3450553T3 (da) | 2020-02-10 |
TR201900649T4 (tr) | 2019-02-21 |
HUE041940T2 (hu) | 2019-06-28 |
US20220354968A1 (en) | 2022-11-10 |
RS58337B1 (sr) | 2019-03-29 |
CY1121348T1 (el) | 2020-05-29 |
LT3122878T (lt) | 2019-02-11 |
SI3122878T1 (sl) | 2019-05-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20190117T1 (hr) | iRNK TERAPIJA ZA LIJEČENJE BOLESTI OKA | |
HK1231417A1 (zh) | 用於治療眼科疾病和障礙的化合物 | |
IL251696A0 (en) | Methods for treating eye diseases | |
EP3212233A4 (en) | Combination therapy for treatment of disease | |
HK1246179A1 (zh) | 治療視網膜疾病的方法 | |
IL250960A0 (en) | Combined treatment of sinecriviroc for the treatment of leprosy | |
HK1258994A1 (zh) | 用於疾病治療的方法 | |
LT3210973T (lt) | Heteroarilo junginiai, skirti akių ligų gydymui | |
GB201412578D0 (en) | Treatment of neurological diseases | |
PL3129483T3 (pl) | Terapia skojarzona do leczenia chorób autoimmunologicznych | |
IL249502A0 (en) | Novel therapeutic uses of benzylideneguanidine derivatives for the treatment of protein-associated diseases | |
EP3154637A4 (en) | Treatment of virus-based diseases of the skin | |
EP3310396A4 (en) | THERAPEUTIC HYDROGELS BASED ON NANOFIBRES FOR THE LOCAL TREATMENT OF BRAIN DISEASES | |
IL259381B (en) | Miravegron for the treatment of retinal diseases | |
PL3302463T3 (pl) | Zastosowanie 3 deoksyantocyjanidyn w leczeniu chorób oczu | |
GB201517565D0 (en) | Treatment of genetic diseases | |
AU2014902075A0 (en) | New Therapeutic Treatment Combination | |
GB201306413D0 (en) | The local treatment of ophthalmic diseases |